Blue Water Biotech announced that it has received a letter from the Nasdaq Stock Market, stating that the Company has regained compliance with the Nasdaq Stock Market, LLC Listing Rule 5250(c)(1). The Rule requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission. On October 20, 2023, BWB filed its Form 10-Q for the period ended June 30, 2023, and thus is now current on its SEC financial reporting obligations.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BWV:
- Blue Water Biotech Signs Non-Binding Term Sheet to Acquire a Commercial Stage Oncology Company
- Blue Water Biotech Announces It Has Regained Compliance with Nasdaq Listing Rule 5250(c)(1)
- Blue Water Biotech prioritizes oncology focus, deprioritizes vaccine programs
- Blue Water Biotech Issues Letter to Shareholders
- Blue Water Biotech Appoints Dr. Neil J. Campbell as President and CEO and Bruce Harmon as CFO
